The early-stage study took place over 12 weeks and included an 82-person healthy control group and 31 individuals with varying stages of cognitive decline.
The largest study ever of its kind enrolled over 400,000 participants from all 50 states in a span of only eight months.
The number comes from a massive RAND Corporation study which included 400,000 participants across the US, Europe and South Africa.
This is significant considering that ILRs have been viewed as the industry gold standard, allowing for long-term surveillance of AFib.
Clinical study utilizes the Zimmer Biomet mymobility app on Apple Watch and iPhone to guide patients through pre- and post-op care.
Researchers used data from 14,000 Apple Watch users and was able to detect that 462 of them had diabetes by using the Watch's heart rate sensor.
The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
The pilot program members will be matched with wireless glucose monitors, mobile apps, lifestyle support and team of healthcare experts.
Up to 10,000 Fitbit Charge 2 and Fitbit Alta HR devices will be provided to a representative sample of the research program volunteers for a one-year study.
Called MyGeneRank, the app allows users with genetic data from 23andMe to obtain an estimated genetic risk score for coronary artery disease.